DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial
Summary
MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS). Understanding the urgent nature and the challenges faced by physicians looking for options to treat COVID-19 patients experiencing rapid deterioration, DSG and the PhaseBio team worked in unison to complete the full study build in a matter of days. Both teams leveraged their combined knowledge and experience to collaborate and identify the most effective way to get the study up and running as quickly as possible; at the same time, considering all future contingencies in order to efficiently conduct the trial as they navigate new realities raised by the pandemic. The team used various modules from the unified eCaseLink™ platform, integrating virtual components such as eConsent and Remote Monitoring with traditional Randomization and EDC solutions to build a fast, comprehensive and intuitive clinical trial system. The operation teams provided inputs on the study challenges and collaborated in finding optimal solutions to build the ideal system in a very short amount of time.
Classifications
AskAI Classifications
LabelsLinked Companies
